Menu

Leadership Team

Sylvain Celanire, PhD - Chief Executive Officer

Sylvain Celanire, PhD - Chief Executive Officer

Sylvain has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector
Carl Bjartmar, MD, PhD - Chief Medical Officer

Carl Bjartmar, MD, PhD - Chief Medical Officer

Carl Bjartmar has more than 20 years of experience in clinical research and development of innovative therapies as global pharma and biotech executive
Frederik Rombouts, PhD - Vice President, Drug Discovery

Frederik Rombouts, PhD - Vice President, Drug Discovery

Frederik has 22 years of drug discovery research and development experience in the neuroscience and oncology therapeutic areas
Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development

Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development

Cédric has 25 years of experience in preclincial research and early clinical development in the therapeutic areas of inflammation, neurology, fibrosis and oncology

Board of Directors

Gerhard Koenig, PhD - Executive Chairman

Gerhard Koenig, PhD - Executive Chairman

Gerhard Koenig is a senior R&D leader with more than 28 years of experience in drug development
Clara Campàs, PhD - Director

Clara Campàs, PhD - Director

Clara Campàs is Managing Partner & co-founder of Asabys Partners
Ward Capoen, PhD - Director

Ward Capoen, PhD - Director

Ward Capoen is a Partner at V-Bio Ventures, which he joined in 2016
Alain Huriez, MD - Director

Alain Huriez, MD - Director

Alain Huriez brings over 30 years of experience in life sciences and finance
Bart De Taeye, PhD - Director

Bart De Taeye, PhD - Director

Bart De Taeye is Senior Investment Manager in the Life Sciences & Care team at PMV
Sylvain Celanire, PhD - CEO & Director

Sylvain Celanire, PhD - CEO & Director

Sylvain Celanire has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector

Scientific Advisory Board

Ludo Van Den Bosch, PhD - Scientific founder / Chairman of the Advisory Board

Ludo Van Den Bosch, PhD - Scientific founder / Chairman of the Advisory Board

Prof. Ludo Van Den Bosch's founding scientific discoveries in CMT, CIPN and ALS diseases, constitute the most advanced assets of Augustine Therapeutics.
Joris de Wit, PhD - Scientific founder

Joris de Wit, PhD - Scientific founder

Joris de Wit is Professor at KU Leuven, Department of Neurosciences, Deputy Science Director of the VIB-KU Leuven Center for Brain and Disease Research.
Philip Van Damme, MD, PhD

Philip Van Damme, MD, PhD

Prof. Van Damme is currently leading the Neuromuscular Reference Center at the University Hospital in Leuven
Davide Pareyson, MD

Davide Pareyson, MD

Dr Pareyson is a Clinical Neurologist at the Fondazione IRCCS Istituto Neurologico C. Besta of Milan, Italy, and Director of the Unit of Rare Neurodegenerative and Neurometabolic Diseases.
Jonathan Baets, MD, PhD

Jonathan Baets, MD, PhD

Prof. Baets is the medical director of the Neuromuscular Reference Center at the Antwerp University Hospital
Tom Lloyd, MD, PhD

Tom Lloyd, MD, PhD

Prof. Lloyd has served as co-director of the Johns Hopkins CMT Center and site Principal Investigator of the Inherited Neuropathy Consortium since 2010.
Guido Cavaletti, MD, PhD

Guido Cavaletti, MD, PhD

Prof. Cavaletti, MD, Ph.D., is a Professor of Human Anatomy, School of Medicine and Surgery, University of Milano-Bicocca
Rainer Freynhagen, MD

Rainer Freynhagen, MD

Dr. Freynhagen is Professor and Chief Physician at the Hospital Benedictus, Tutzing, Germany
Hans Wildiers, MD

Hans Wildiers, MD

Dr. Wildiers is a medical oncologist dedicated to breast cancer clinical research and development
Nicholas Carruthers, PhD

Nicholas Carruthers, PhD

Dr. Carruthers is a medicinal chemist with over 30 years of broad, R&D-specific, executive experience within the pharmaceutical industry

Investors

© 2025 Augustine
A thinline.be | soon production